|
End-of-day quote
Oslo Bors
|
5-day change | 1st Jan Change | ||
| - PTS | -.--% |
|
-.--% | - |
| 08-06 | Nykode Therapeutics Asa Announces Appointment of Jakob Helding Rasmussen as Chief Technology Officer | CI |
| 08-04 | Nykode Therapeutics Flags Delay in Draft Recommendation for Tax Appeal in Norway | MT |
Company Valuation: VACY AS
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 23,372 | 8,287 | 6,988 | 994.7 | 787.6 | 1,122 | - | - |
| Change | - | -64.54% | -15.67% | -85.77% | -20.81% | 42.41% | - | - |
| Enterprise Value (EV) 1 | 21,490 | 6,164 | 5,327 | -251.9 | 236.2 | 636.6 | 544.2 | 668.9 |
| Change | - | -71.32% | -13.58% | -104.73% | 193.76% | 169.47% | -14.52% | 22.92% |
| P/E | -307x | -18.1x | -16.8x | -2.28x | -6.31x | -5.31x | -37.1x | -12.4x |
| PBR | - | 5.11x | 3.85x | 0.66x | 0.9x | 1.73x | 1.55x | 1.86x |
| PEG | - | -0x | 0.9x | -0.44x | 0.1x | -0.1x | 0.4x | -0x |
| Capitalization / Revenue | 74.5x | 88.8x | 49.5x | 9.75x | 182x | - | 6.94x | 16.2x |
| EV / Revenue | 68.5x | 66.1x | 37.8x | -2.47x | 54.6x | - | 3.37x | 9.65x |
| EV / EBITDA | -244x | -11.4x | -8.99x | 0.49x | -0.93x | -2.38x | -6.54x | -4.26x |
| EV / EBIT | -228x | -11.2x | -8.66x | 0.47x | -0.87x | -2.34x | -6.54x | -4.39x |
| EV / FCF | 8,641x | -25.5x | -5.11x | 0.44x | -0.84x | -4.59x | -9.82x | -4.67x |
| FCF Yield | 0.01% | -3.92% | -19.6% | 227% | -119% | -21.8% | -10.2% | -21.4% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.2627 | -1.55 | -1.271 | -1.336 | -0.382 | -0.6465 | -0.0925 | -0.2775 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 313.5 | 93.31 | 141.1 | 102 | 4.326 | - | 161.7 | 69.3 |
| EBITDA 1 | -87.93 | -542.7 | -592.6 | -513.1 | -253.5 | -268 | -83.16 | -157.1 |
| EBIT 1 | -94.36 | -549.3 | -615.1 | -538.1 | -273 | -272.6 | -83.16 | -152.5 |
| Net income 1 | -82.32 | -441.7 | -372.3 | -432.2 | -116.9 | -207.9 | -41.58 | -97.02 |
| Net Debt 1 | -1,882 | -2,123 | -1,661 | -1,247 | -551.4 | -485.1 | -577.5 | -452.8 |
| Reference price 2 | 80.700 | 28.120 | 21.400 | 3.046 | 2.412 | 3.435 | 3.435 | 3.435 |
| Nbr of stocks (in thousands) | 289,619 | 294,694 | 326,546 | 326,546 | 326,546 | 326,546 | - | - |
| Announcement Date | 3/31/22 | 2/28/23 | 2/28/24 | 2/26/25 | 2/25/26 | - | - | - |
1NOK in Million2NOK
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 21.38x | 7.5x | 15.3x | 1.35% | 71.56B | |
| 31.01x | 7.89x | 24.08x | 0.05% | 54.43B | |
| -79.85x | 14.92x | -76.15x | -.--% | 27.59B | |
| 30.34x | 5.94x | 15.73x | -.--% | 23.91B | |
| -14.5x | 5.07x | -6.61x | -.--% | 23.14B | |
| 25.57x | 4.84x | 16.25x | -.--% | 18.65B | |
| 58.2x | 20.62x | 42.08x | 0.07% | 18.64B | |
| -1217.84x | 38.05x | -15079.66x | -.--% | 16.01B | |
| 15.7x | 4.62x | 10.79x | -.--% | 12.54B | |
| Average | -125.56x | 12.16x | -1,670.91x | 0.16% | 29.61B | |
| Weighted average by Cap. | -61.29x | 10.43x | -899.29x | 0.38% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- VACC Stock
- VACC Stock
- Valuation VACY AS
Select your edition
All financial news and data tailored to specific country editions
